| 32.6 0.2 (0.62%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 42.32 | 1-year : | 45.52 |
| Resists | First : | 36.23 | Second : | 38.97 |
| Pivot price | 33.95  |
|||
| Supports | First : | 31.79 | Second : | 26.45 |
| MAs | MA(5) : | 32.52 |
MA(20) : | 34.66 |
| MA(100) : | 36.84 |
MA(250) : | 36.4  |
|
| MACD | MACD : | -1.2 |
Signal : | -1 |
| %K %D | K(14,3) : | 18.3 |
D(3) : | 16.5 |
| RSI | RSI(14): 36 |
|||
| 52-week | High : | 44.95 | Low : | 29.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PGNY ] has closed above bottom band by 24.6%. Bollinger Bands are 17.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.63 - 32.79 | 32.79 - 32.93 |
| Low: | 31.6 - 31.78 | 31.78 - 31.95 |
| Close: | 32.31 - 32.59 | 32.59 - 32.85 |
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Tue, 23 Apr 2024
Progyny, Inc. (NASDAQ:PGNY) Shares Sold by Jennison Associates LLC - MarketBeat
Sun, 21 Apr 2024
Kornitzer Capital Management Inc. KS Has $25.51 Million Position in Progyny, Inc. (NASDAQ:PGNY) - MarketBeat
Wed, 03 Apr 2024
Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)? - Simply Wall St
Wed, 27 Mar 2024
Progyny, Inc.'s (NASDAQ:PGNY) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? - Yahoo Finance
Tue, 26 Mar 2024
PGNY Stock Quote Price and Forecast - CNN
Fri, 15 Mar 2024
Progyny, Inc: Long-Term Outlook Remains Positive, Reiterate Buy (NASDAQ:PGNY) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 96 (M) |
| Shares Float | 84 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 101.5 (%) |
| Shares Short | 6,530 (K) |
| Shares Short P.Month | 6,480 (K) |
| EPS | 0.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.78 |
| Profit Margin | 5.6 % |
| Operating Margin | 5.1 % |
| Return on Assets (ttm) | 5.9 % |
| Return on Equity (ttm) | 13.3 % |
| Qtrly Rev. Growth | 26 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 11.34 |
| EBITDA (p.s.) | 0.67 |
| Qtrly Earnings Growth | 364.5 % |
| Operating Cash Flow | 189 (M) |
| Levered Free Cash Flow | 161 (M) |
| PE Ratio | 52.58 |
| PEG Ratio | 3.2 |
| Price to Book value | 5.64 |
| Price to Sales | 2.87 |
| Price to Cash Flow | 16.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|